SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Study Results Published in The New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism